Associated Genetic Biomarkers
NCI Definition: A neuroblastic tumor characterized by the presence of neuroblastic cells, ganglion cells, and a stroma with Schwannian differentiation constituting more than fifty-percent of the tumor volume. There are two histologic subtypes identified: ganglioneuroblastoma, intermixed and ganglioneuroblastoma, nodular. 
Ganglioneuroblastomas most frequently harbor alterations in RNF43, RBM10, RARA, PPM1D, and BRIP1 .
PPM1D Amplification, BRIP1 Amplification, ALK Mutation, ALK Missense, and ALK Codon 1174 Missense are the most common alterations in ganglioneuroblastoma .
There are 6 clinical trials for ganglioneuroblastoma, of which 5 are open and 1 is completed or closed. Of the trials that contain ganglioneuroblastoma as an inclusion criterion, 1 is phase 1 (1 open), 2 are phase 2 (1 open), 2 are phase 3 (2 open), and 1 is no phase specified (1 open).
Hyperdiploidy and MYCN are the most frequent gene inclusion criteria for ganglioneuroblastoma clinical trials .
Cyclophosphamide, carboplatin, and dinutuximab are the most common interventions in ganglioneuroblastoma clinical trials.
Significant Genes in Ganglioneuroblastoma
MYCN is an inclusion eligibility criterion in 1 clinical trial for ganglioneuroblastoma, of which 1 is open and 0 are closed. Of the trial that contains MYCN status and ganglioneuroblastoma as inclusion criteria, 1 is phase 2 (1 open) .
2. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 8. This dataset does not represent the totality of the genetic landscape; see paper for more information.